Division of Adult Neurology, Department of Neurosciences, University of The Philippines Manila - Philippine General Hospital, Manila, The Philippines.
Department of Clinical Epidemiology, College of Medicine, University of The Philippines Manila, Manila, The Philippines.
Neurodegener Dis Manag. 2021 Apr;11(2):177-185. doi: 10.2217/nmt-2020-0051. Epub 2021 Mar 11.
Intravenous methylprednisolone (IVMP) is previously given to secondary progressive multiple sclerosis (SPMS) patients. This study aimed to re-examine the effects of IVMP in SPMS. Major electronic databases were searched for randomized controlled trials. Four randomized controlled trials were included. IVMP may be inferior to mitoxantrone (MTX) in terms of expanded disability status scale (EDSS) improvement. There was no significant difference in terms of EDSS reduction and magnetic resonance imaging (MRI) plaque reduction when IVMP + MTX were compared with MTX. There is no significant difference between IVMP and cyclophosphamide based on EDSS progression and relapse reduction. IVMP should not be routinely used as treatment for SPMS and is not recommended as an alternative treatment for SPMS.
静脉注射甲基强的松龙（IVMP）以前用于治疗继发进展型多发性硬化症（SPMS）患者。本研究旨在重新评估 IVMP 在 SPMS 中的作用。主要电子数据库中检索到随机对照试验。纳入了四项随机对照试验。IVMP 在扩展残疾状况量表（EDSS）改善方面可能劣于米托蒽醌（MTX）。当 IVMP + MTX 与 MTX 相比时，在 EDSS 降低和磁共振成像（MRI）斑块减少方面没有显著差异。IVMP 在 EDSS 进展和复发减少方面与环磷酰胺没有显著差异。IVMP 不应该常规用于治疗 SPMS，也不建议作为 SPMS 的替代治疗。
